These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12570953)

  • 21. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction.
    Ewald B; Ewald D; Thakkinstian A; Attia J
    Intern Med J; 2008 Feb; 38(2):101-13. PubMed ID: 18290826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) as a Diagnostic Biomarker of Left Ventricular Systolic Dysfunction in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).
    Andrijevic I; Milutinov S; Lozanov Crvenkovic Z; Matijasevic J; Andrijevic A; Kovacevic T; Bokan D; Zaric B
    Lung; 2018 Oct; 196(5):583-590. PubMed ID: 29951921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes.
    Epshteyn V; Morrison K; Krishnaswamy P; Kazanegra R; Clopton P; Mudaliar S; Edelman S; Henry R; Maisel A
    Diabetes Care; 2003 Jul; 26(7):2081-7. PubMed ID: 12832317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening.
    Xanthakis V; Larson MG; Wollert KC; Aragam J; Cheng S; Ho J; Coglianese E; Levy D; Colucci WS; Michael Felker G; Benjamin EJ; Januzzi JL; Wang TJ; Vasan RS
    J Am Heart Assoc; 2013 Nov; 2(6):e000399. PubMed ID: 24200688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from 'PREDICTOR', a population based-study in central Italy.
    Mureddu GF; Tarantini L; Agabiti N; Faggiano P; Masson S; Latini R; Cesaroni G; Miceli M; Forastiere F; Scardovi AB; Uguccioni M; Boccanelli A
    Eur J Heart Fail; 2013 Oct; 15(10):1102-12. PubMed ID: 23787717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of phonoelectrocardiographic left ventricular systolic time intervals and B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction.
    Moyers B; Shapiro M; Marcus GM; Gerber IL; McKeown BH; Vessey JC; Jordan MV; Huddleston M; Foster E; Chatterjee K; Michaels AD
    Ann Noninvasive Electrocardiol; 2007 Apr; 12(2):89-97. PubMed ID: 17593176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population.
    Nakamura M; Endo H; Nasu M; Arakawa N; Segawa T; Hiramori K
    Heart; 2002 Feb; 87(2):131-5. PubMed ID: 11796549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Left ventricular systolic dysfunction in rheumatoid disease: an unrecognized burden?
    Bhatia GS; Sosin MD; Patel JV; Grindulis KA; Khattak FH; Hughes EA; Lip GY; Davis RC
    J Am Coll Cardiol; 2006 Mar; 47(6):1169-74. PubMed ID: 16545648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic accuracy of natriuretic peptide screening for left ventricular systolic dysfunction in the community: systematic review and meta-analysis.
    Goyder CR; Roalfe AK; Jones NR; Taylor KS; Plumptre CD; James O; Fanshawe TR; Hobbs FDR; Taylor CJ
    ESC Heart Fail; 2023 Jun; 10(3):1643-1655. PubMed ID: 36785511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic ability of B-type natriuretic peptide and impedance cardiography: testing to identify left ventricular dysfunction in hypertensive patients.
    Bhalla V; Isakson S; Bhalla MA; Lin JP; Clopton P; Gardetto N; Maisel AS
    Am J Hypertens; 2005 Feb; 18(2 Pt 2):73S-81S. PubMed ID: 15752936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction.
    Goetze JP; Mogelvang R; Maage L; Scharling H; Schnohr P; Sogaard P; Rehfeld JF; Jensen JS
    Eur Heart J; 2006 Dec; 27(24):3004-10. PubMed ID: 17118955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy.
    Lukowicz TV; Fischer M; Hense HW; Döring A; Stritzke J; Riegger G; Schunkert H; Luchner A;
    Eur J Heart Fail; 2005 Jun; 7(4):525-31. PubMed ID: 15921790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction.
    Murtagh G; Dawkins IR; O'Connell R; Badabhagni M; Patel A; Tallon E; O'Hanlon R; Ledwidge MT; McDonald KM
    Eur J Heart Fail; 2012 May; 14(5):480-6. PubMed ID: 22416086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B-type natriuretic peptide level in the diagnosis of asymptomatic diastolic dysfunction.
    Karaca I; Gülcü E; Yavuzkir M; Dağli N; Ilkay E; Ozbay Y; Işik A; Arslan N
    Anadolu Kardiyol Derg; 2007 Sep; 7(3):262-7. PubMed ID: 17785213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width.
    Goode KM; Clark AL; Cleland JG
    Int J Cardiol; 2008 Nov; 130(3):426-37. PubMed ID: 18178273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study.
    Betti I; Castelli G; Barchielli A; Beligni C; Boscherini V; De Luca L; Messeri G; Gheorghiade M; Maisel A; Zuppiroli A
    J Card Fail; 2009 Jun; 15(5):377-84. PubMed ID: 19477397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction.
    Maisel AS; Koon J; Krishnaswamy P; Kazenegra R; Clopton P; Gardetto N; Morrisey R; Garcia A; Chiu A; De Maria A
    Am Heart J; 2001 Mar; 141(3):367-74. PubMed ID: 11231433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical criteria and biochemical markers for the detection of systolic dysfunction.
    Yamamoto K; Burnett JC; Bermudez EA; Jougasaki M; Bailey KR; Redfield MM
    J Card Fail; 2000 Sep; 6(3):194-200. PubMed ID: 10997744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.
    Vanderheyden M; Bartunek ; Claeys G; Manoharan G; Beckers JF; Ide L
    Clin Biochem; 2006 Jun; 39(6):640-5. PubMed ID: 16516185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease.
    Crowson CS; Myasoedova E; Davis JM; Roger VL; Karon BL; Borgeson D; Rodeheffer RJ; Therneau TM; Gabriel SE
    Arthritis Care Res (Hoboken); 2011 May; 63(5):729-34. PubMed ID: 21225672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.